Pharmacokinetics and pharmacodynamics of L-DOPA after acute and 6-week tolcapone administration in patients with Parkinson's disease

Clinical Neuropharmacology

Volumn 22, Issue 1, 1999, Pages 24-29

  Napolitano, Alessandro ^b   Del Dotto, Paolo ^b   Petrozzi, Lucia ^b   Dell'Agnello, Grazia ^b   Bellini, Giovanna ^b   Gambaccini, Gianna ^b   Bonuccelli, Ubaldo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b NONE

Author keywords

Catechol O methyltransferase; L Dopa; Motor fluctuations; Parkinson's disease; Tolcapone

Indexed keywords

3 O METHYLDOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; LEVODOPA; TOLCAPONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL;

EID: 0032960571     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199901000-00005     Document Type: Article

References (24)

1. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-81.
2. Wooten GF. Progress in understanding the pathophysiology of treatment-related fluctuations in Parkinson's disease. Ann Neurol 1988; 24:363-5.
3. Nutt JG, Holford NHG. The response to levodopa in Parkinson's disease: imposing pharmacological law and order. Ann Neurol 1996;39:561-73.
4. Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984;7:35-49.
5. Da Prada M, Keller HH, Pieri L, Kettler R, Haefely WE. The pharmacology of Parkinson's disease: basic aspects and recent advances. Experientia 1984;40:1165-72.
6. Kopin IJ. Catecholamine metabolism: basic aspects and clinical significance. Pharmacol Rev 1985;37:333-64.
7. Zürcher G, Dingemanse J, Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Adv Neurol 1993;60: 641-7.
8. Da Prada M, Borgulya J, Napolitano A, Zürcher G. Improved therapy of Parkinson's disease by tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine sparing effect. Clin Neuropharmacol 1994;17(Suppl 3):S26-S37.
9. Roberts JW, Cora-Locatelli G, Bravi D, Amantea MA, Mouradian MM, Chase TN. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993;43:2685-8.
10. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995;40:253-62.
11. Guttman M. COMT inhibition: new hopes in the management of Parkinson's disease. Focus on Parkinson's Disease 1995;7:58-61.
12. Limousin P, Pollak P, Pfefen P, Tournier-Gervason CL, Dubuis R, Perret SE. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease. Clin Neuropharmacol 1995;18:258-65.
13. Kurth MC, Adler CH, Saint-Hilaire MH, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations. Neurology 1997;48:81-7.
14. Rajput AH, Martin W, Saint-Hilaire MH, Dorflinger E, Pedder S. Tolcapone improves motor function in parkinsonian patients with the wearing-off phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997;49:1066-71.
15. Fahn S, Elton RL, and members of the UPDRS committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent Developments in Parkinson's Disease. Florham Park, NJ: MacMillan Heathcare Information, 1987:153-63.
16. Gerlach M, Klaunzer N, Pruntzek H. Determination of L-Dopa and 3-O-methyldopa in human plasma by extraction using C18 cartridges followed by high-performance liquid chromatographic analysis with electrochemical detection. J Chromatogr 1986;380: 379-85.
17. Davis TL, Roznoski M, Burns RS. Effects of tolcapone in Parkinson's patients taking 1-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 1995;10:349-51.
18. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994;44:913-9.
19. Gancher ST, Nutt JG, Woodward WR. Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients. Neurology 1987;37:940-4.
20. Yeh KC, August TF, Bush DF, et al. Pharmacokinetics and bioavailability of Sinemet CR: A summary of human studies. Neurology 1989;39(suppl 2):25-38.
21. Acquas E, Carboni E, de Ree RAH, Da Prada M, Di Chiara G. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592. J Neurochem 1992;59:326-30.
22. Napolitano A, Zürcher G, Da Prada M. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-DOPA and dopamine in rats. Eur J Pharmacol 1995;273:215-21.
23. Duodet DJ, Chan GLY, Holden JE, Morrison KS, Wyatt RJ, Ruth TJ. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology 1997;36: 363-71.
24. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Neurology 1997;49:665-71.